Condition: Open Angle Glaucoma (OAG) · NAION( Non-arteritic Anterior Ischemic Optic Neuropathy) · Sponsor: Life Biosciences Inc.
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 safe when given as a single dose to people with OAG or NAION * What side effects may occur, if any, after taking ER-100? Participants will: * Receive a single dose of ER-100 * Undergo safety assessments including detailed eye examination and laboratory tests * Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body * Complete questionnaires about their quality of life * Be followed for up to 5 years to monitor long-term health and vision outcomes
This description comes directly from the study's public registry record.
Life Biosciences · (857) 400-9245 · ER100trial@lifebiosciences.com
Always discuss trial participation with your own doctor first.
| Global Research Management, Inc. | Glendale, California, United States | Recruiting |
| Mass Eye and Ear | Boston, Massachusetts, United States | Recruiting |
| Columbia University Irving Medical Center/Edward S. Harkness Eye Institute | New York, New York, United States | Recruiting |
| Charleston Neuroscience Institute | Charleston, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07290244